BioVie appoints Amy Chappell, Kameel Farag to board of directors

BioVie (BIVI) announced the appointment of Amy Chappell, MD, FAAN, and Kameel Farag to its Board of Directors. Currently, as CMO of Solaxa Inc., Chappelloversees clinical development of novel therapies for ataxia and nerve repair. Most recently, as CFO and head of business operations at Aspen Neuroscience, Farag oversaw tripling the company’s headcount, secured over $150M in financing, built manufacturing infrastructure, and prepared the company for clinical data and a potential future public offering.